Knowthestock.com
CERS - Cerus Corp.

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

31%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 7.78%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -10.39%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 2.39
Debt Ratio is 0.72
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.42
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cerus Corp. (CERS) - http://www.cerus.com/
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Exchange - NASDAQ
Industry -
Sector -
CEO - William Greenman
Employees - 406
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.